Dose Insider / Glossary / LEADER trial

LEADERThe heart trial of liraglutide in type 2 diabetes

Updated November 20, 2026 · 3 min read · Marso et al., N Engl J Med 2016; VICTOZA label

LEADER is the cardiovascular trial of liraglutide, the GLP-1 medicine sold as Victoza for type 2 diabetes. It enrolled 9,340 adults with type 2 diabetes and high cardiovascular risk and followed them for a median of 3.8 years on liraglutide or placebo.

13.0%Major heart events, Liraglutide, events over a median 3.8 years
Events over a median 3.8 yearsLEADER, % of patientsMAJOR HEART EVENTSLiraglutide13.0%Placebo14.9%DEATH FROM ANY CAUSELiraglutide8.2%Placebo9.6%Events over a median 3.8yearsLEADER, % of patientsMAJOR HEART EVENTSLiraglutide13.0%Placebo14.9%DEATH FROM ANY CAUSELiraglutide8.2%Placebo9.6%

Cardiovascular death 4.7% against 6.0%, a hazard ratio of 0.78.

On this page

A first heart attack, stroke or cardiovascular death occurred in 13.0% on liraglutide against 14.9% on placebo, and deaths from cardiovascular causes and from any cause were lower too. It was published in the New England Journal of Medicine in 2016.1

How the trial was run

LEADER was double-blind and compared liraglutide with placebo on top of usual care. Its first aim was safety: to show that liraglutide did not raise heart risk, with a margin of 1.30 for the upper bound of the hazard ratio. The main outcome was the first of three events: cardiovascular death, non-fatal heart attack or non-fatal stroke.1 The Victoza label describes the participants as adults with inadequately controlled type 2 diabetes and atherosclerotic cardiovascular disease, randomized to Victoza 1.8 mg or placebo for a median of 3.5 years.2

Who took part matters for reading the result. The label says 80% of participants were 50 or older with established heart, brain or peripheral artery disease, chronic kidney disease or moderate heart failure, and 20% were 60 or older with other cardiovascular risk factors. The average age was 64, and 64.3% were men.2 So LEADER mostly describes older people who already had vascular disease, the group in which the Victoza heart indication applies.

What it found

Marso et al., 2016.1

The trial met its safety goal and showed that liraglutide was better than placebo on the main outcome. On that basis Victoza is approved to reduce the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.2

Side effects and safety

Stomach and gut events were the most common reason people stopped liraglutide. Pancreatitis, a concern raised about the class, was slightly less frequent on liraglutide than on placebo, without a statistically clear difference.1 On the Saxenda dose for weight, 3 mg, nausea was reported by 39.3% against 13.8% on placebo.3 Our page on nausea on a GLP-1 covers what helps.

Among the heart trials

Other heart trials of GLP-1 medicines used the same three-part outcome: SUSTAIN 6 for semaglutide found 6.6% against 8.9% over two years, REWIND for dulaglutide 12.0% against 13.4% over 5.4 years, and Harmony Outcomes for albiglutide 7% against 9%.4,5,6 Because the trials enrolled different people for different lengths of time, the percentages are not directly comparable; the hazard ratios, between 0.74 and 0.88, tell a more consistent story.

How to read the result

The difference on the main outcome, 13.0% against 14.9%, means about 2 fewer people in every 100 had a major heart event over the trial. That is a rough figure we calculated from the published percentages. The fall in deaths from any cause, from 9.6% to 8.2%, was a secondary result, measured alongside the main one.1

Limits

LEADER studied liraglutide at 1.8 mg in people with type 2 diabetes and high heart risk; it does not describe the 3 mg weight dose or people without diabetes. It was funded by Novo Nordisk and the U.S. National Institutes of Health.1

Sources

  1. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER). N Engl J Med 2016;375:311-322. Funded by Novo Nordisk and the National Institutes of Health; NCT01179048. doi:10.1056/NEJMoa1603827
  2. VICTOZA (liraglutide) injection prescribing information. Novo Nordisk; DailyMed, version published November 17, 2025; sections 1 and 14. dailymed.nlm.nih.gov
  3. SAXENDA (liraglutide) injection prescribing information. Novo Nordisk; DailyMed, version published June 15, 2026; section 6.1. dailymed.nlm.nih.gov
  4. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). N Engl J Med 2016;375:1834-1844. doi:10.1056/NEJMoa1607141
  5. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND). Lancet 2019;394:121-130. doi:10.1016/S0140-6736(19)31149-3
  6. Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes). Lancet 2018;392:1519-1529. doi:10.1016/S0140-6736(18)32261-X

Related analyses

Log your doses, blood sugar and blood pressure in one place.

Open Dose Insider